Back

Histology-verified myocardial fibrosis and quantification in severe AS patients: correlation with non-invasive LV myocardial tissue assessment

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Pathomechanisms and treatment of valve disease Valvular Heart Disease ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Sergio Maltes

Hospital Santa Cruz, Lisbon (Portugal)

5 More presentations in this session

Presentation thumbnail
Loss of ceramide synthase 5 reduces the development of aortic valve stenosis in mice with high fat diet.
Ms L. Reese (Bonn, DE)
Abstract Slides
Presentation thumbnail
Non-vitamin K antagonist oral anticoagulants (NOACs) attenuate valvular calcification in patients with severe aortic stenosis
Ms M. Kopytek (Krakow, PL)
Abstract Slides
Presentation thumbnail
Unravelling the role of SOCS3 in aortic valve stenosis
Doctor H. Billig (Bonn, DE)
Abstract Slides
Presentation thumbnail
Specific gene domains most commonly affected by CHIP-driver mutations predicting mortality in severe aortic stenosis after transcatheter aortic valve implantation
Associate Professor S. Mas-Peiro (Frankfurt, DE)
Abstract Slides
Presentation thumbnail
Autologous or bovine pericardium for aortic cusp replacement? Histomorphological and biomechanical properties as decision making tools
Doctor C. Dittfeld (Dresden, DE)
Abstract Slides

Access the full session

Session thumbnail
Pathomechanisms and treatment of valve disease

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Session
Acute heart failure and valvular heart disease
thumbnail
Congress Session
How to manage valvular heart disease in heart failure
thumbnail
Congress Presentation
Transcatheter therapies for structural heart disease: where are we in 2023?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources